SAGE Sage Therapeutics Inc.

130.74
-6.55  -5%
Previous Close 137.29
Open 134.81
Price To Book 6.2
Market Cap 6130029129
Shares 46,887,174
Volume 628,977
Short Ratio
Av. Daily Volume 660,804

SEC filingsSee all SEC filings

  1. 8-K - Current report 19537989
  2. 8-K - Current report 19512170
  3. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 181240925
  4. CT ORDER - Confidential treatment order 181213342
  5. 8-K - Current report 181195649

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date extended three months to March 19, 2018. Advisory Committee meeting November 2, 2018 voted 17-1 recommending approval.
Brexanolone - SAGE-547 (202C)
Postpartum Depression - moderate
Phase 3 data due 2020.
SAGE-217
Major Depressive Disorder (MDD)
Phase 3 data met primary endpoint - January 7, 2019.
SAGE-217
Postpartum depression (PPD)
Phase 3 data released November 9, 2017. Primary endpoint met.
Brexanolone - SAGE-547 (202B)
Postpartum Depression (Severe)
Phase 3 data released September 12, 2017 - primary endpoint not met.
SAGE-547
SRSE
Phase 3 data due 2020.
SAGE-217
Insomnia
Phase 2 Part A data due 1H 2019.
SAGE-217
Bipolar depression
Phase 1 data due 2H 2019.
SAGE-718
Huntington's disease
Phase 1 data due 1H 2019.
SAGE-324
Essential tremor

Latest News

  1. Sage Therapeutics Appoints Elizabeth Barrett and George Golumbeski to Board of Directors
  2. Ligand (LGND) Takes a Hit on Citron's Negative Research Report
  3. See what the IHS Markit Score report has to say about SAGE Therapeutics Inc.
  4. Citron Says Ligand Has 80% Downside in Explosive Note
  5. Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics
  6. 3 Small-Cap Stocks With Big-Cap Potential
  7. Here's How The Government Shutdown Will Affect These Medical Stocks
  8. The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference
  9. 3 Biggest Stories at the J.P. Morgan Healthcare Conference This Year
  10. Eyeing FDA approval, Sage lays out strategy for dual postpartum depression drugs
  11. Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus
  12. Here's Why Axsome Therapeutics Has Been a Rocket Ship This Week
  13. Biotech Stocks Post Double-Digit Gains in Monday Surge
  14. What Happened in the Stock Market Today
  15. Three Healthcare Stocks Rallying Over 10% Today
  16. Sage Therapeutics's stock shoots higher after postpartum depression treatment's positive trial results
  17. Why Sage Therapeutics Is Skyrocketing Today
  18. SAGE Therapeutics Soars on Promising Postpartum Drug-Trial Results
  19. Sage Therapeutics: Results from the Phase 3 ROBIN Trial

SEC Filings

  1. 8-K - Current report 19537989
  2. 8-K - Current report 19512170
  3. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 181240925
  4. CT ORDER - Confidential treatment order 181213342
  5. 8-K - Current report 181195649
  6. S-8 - Securities to be offered to employees in employee benefit plans 181166583
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 181161530
  8. 8-K - Current report 181161441
  9. 8-K - Current report 181158148
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18996295